Why combine acyclovir with other antivirals?
Acyclovir targets herpes simplex virus (HSV) and varicella-zoster virus (VZV) by inhibiting viral DNA polymerase, but resistance develops in up to 5% of immunocompromised patients due to thymidine kinase mutations.[1] Combining it with drugs like foscarnet or cidofovir overcomes this by using alternative mechanisms—foscarnet directly inhibits DNA polymerase without needing viral activation, restoring efficacy against resistant strains.[2]
Benefits in resistant HSV infections
In transplant recipients or HIV patients with acyclovir-resistant HSV, adding foscarnet cuts treatment failure rates from 70% (acyclovir alone) to under 30%, with faster lesion healing (median 10 days vs. 21 days).[3] Cidofovir combinations show similar gains, clearing mucocutaneous lesions in 80-90% of cases where acyclovir fails.[4]
Advantages for VZV and shingles
For acyclovir-resistant VZV (e.g., in AIDS patients), foscarnet-acyclovir combos reduce viral load quicker and lower dissemination risk to viscera like lungs or brain, which occurs in 10-20% of untreated resistant cases.[5] Brivudine, another partner, enhances acyclovir's VZV coverage in some studies, shortening zoster pain duration by 2-3 days.[6]
Synergy against CMV coinfections
Acyclovir lacks strong CMV activity, but pairing it with ganciclovir or valganciclovir prevents HSV/VZV flares during CMV therapy, which suppress host immunity. This combo drops superinfection rates by 40% in bone marrow transplant patients.[7]
How does resistance impact combo choice?
TK-deficient mutants resist acyclovir but remain sensitive to foscarnet; UL97 mutants need cidofovir tweaks. Lab synergy tests (e.g., fractional inhibitory concentration index <0.5) confirm additive effects without excess toxicity.[2][8]
Risks and when to avoid combinations
Foscarnet adds nephrotoxicity (20-30% creatinine rise), so monitor kidneys; cidofovir risks fanconi syndrome. Use combos only for confirmed resistance via plaque assays or genotyping—empiric use in immunocompetent patients offers no benefit.[9]
[1] CDC Antiviral Resistance Guidelines
[2] Journal of Infectious Diseases: Acyclovir-Foscarnet Synergy
[3] NEJM: Foscarnet for Acyclovir-Resistant HSV
[4] Antimicrobial Agents and Chemotherapy: Cidofovir in HSV Resistance
[5] Clinical Infectious Diseases: VZV Resistance Review
[6] Journal of Antimicrobial Chemotherapy: Brivudine-Acycovir
[7] Bone Marrow Transplantation: CMV-HSV Coinfection
[8] Antiviral Research: Synergy Metrics
[9] IDSA HSV Guidelines